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Abstract: Atrial fibrillation (AF) is the most common cardiac arrhythmia, and it is associated with
an increased risk of heart failure, stroke, dementia, and death. Recently, titin-truncating variants
(TTNtv), which are predominantly associated with dilated cardiomyopathy (DCM), were associated
with early-onset AF. Furthermore, genome-wide association studies (GWAS) associated AF with
other structural genes. In this study, we investigated whether early-onset AF was associated with
loss-of-function variants in DCM-associated genes encoding cytoskeletal proteins. Using targeted
sequencing, we examined a cohort of 527 Scandinavian individuals with early-onset AF and a control
group of individuals free of AF (n = 383). The patients had onset of AF before 50 years of age, normal
echocardiogram, and no other cardiovascular disease at onset of AF. We identified six individuals
with rare loss-of-function variants in three different genes (dystrophin (DMD), actin-associated
LIM protein (PDLIM3), and fukutin (FKTN)), of which two variants were novel. Loss-of-function
variants in cytoskeletal genes were significantly associated with early-onset AF when patients were
compared with controls (p = 0.044). Using publicly available GWAS data, we performed genetic
correlation analyses between AF and 13 other traits, e.g., showing genetic correlation between
AF and non-ischemic cardiomyopathy (p = 0.0003). Our data suggest that rare loss-of-function
variants in cytoskeletal genes previously associated with DCM may have a role in early-onset AF,
perhaps through the development of an atrial cardiomyopathy.
Keywords: atrial fibrillation; genetics; arrhythmia; cardiology; next-generation sequencing;
cardiomyopathy
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1. Introduction
Atrial fibrillation (AF) is the most common cardiac arrhythmia and affects more than 30 million
individuals worldwide [1]. AF is associated with an increased risk of serious complications such
as stroke, heart failure, dementia, and death [2]. At present, the disease represents a significant
healthcare burden [3], and the prevalence is expected to increase more than two-fold in the coming
decades [4]. The complex pathophysiological mechanisms behind AF initiation and maintenance
are not yet completely understood. Current pharmacological treatments are limited in efficacy or
associated with significant adverse effects [5]. AF also has a genetic component, which currently
includes 166 common genetic variants [6] and rare variants in a variety of genes [7]. Whereas AF is
traditionally regarded as an electrical disease, two recent studies identified loss-of-function (LOF)
variants in the structural sarcomere gene titin (TTN) to be significantly enriched in early-onset AF
patients [8,9]. In addition, several large genome-wide association studies (GWAS) associated structural
genes with the disease [6,10], and an expert consensus document from several scientific societies
suggested AF to overlap with an atrial cardiomyopathy [11].
There is substantial evidence that genes encoding cytoskeletal proteins are involved in skeletal
muscle myopathies, many of which also have cardiac involvement [12]. Interestingly, the cytoskeletal
gene SGCG, encoding the gamma-sarcoglycan protein, was recently associated with AF in a large
GWAS [6]. SGCG was previously associated with skeletal muscle myopathies, and it is thought to
be linked with dilated cardiomyopathy (DCM) [13]. The newly identified association between SGCG
and AF suggests that cytoskeletal genes might play a role in AF, supporting the hypothesis of an
atrial cardiomyopathy.
Here, we aim to assess the role of cytoskeletal genes in AF, by focusing on rare LOF variants in a
highly selected cohort of AF patients with early onset of disease.
2. Materials and Methods
2.1. Study Populations
Our case population included 527 Danish and Norwegian patients with onset of AF at age < 50
and presenting with no other cardiovascular disease. The diagnosis of AF was defined by ICD-10 code
I48. Patients with diabetes, hypertension, hyperthyroidism, congenital heart disease, valvular heart
disease, or congestive heart failure were excluded. We also excluded patients with a left ventricular
ejection fraction <55%, as determined by echocardiographic examination. Danish patients were
identified through the National Danish Patient Registry, while Norwegian patients were identified
and recruited through clinical practice and the Norwegian Atrial Fibrillation Registry. The study was
approved by the Scientific Ethics Committee of Copenhagen and Frederiksberg (Protocol reference
number: H-KF-01313322) and the Regional Ethics Committee (REK) in Norway (Protocol reference
number: 2009/2224-5).
The control population consisted of 383 Danish individuals from the Copenhagen Holter Study.
These individuals were monitored for arrhythmia with Holter monitors for 48 h and were known to be
free of AF and cardiovascular disease. The cohort was previously described in detail elsewhere [14].
Characteristics of the study populations are summarized in Table 1. The control group was approved
by the Scientific Ethics Committee of Copenhagen and Frederiksberg (Protocol reference number:
KF 01 25304).
2.2. Genetic Sequencing
We extracted genomic DNA (gDNA) from leukocytes in peripheral blood samples from study
participants in both case and control populations. The gDNA was fragmented with endonucleases and
hybridized with gene-specific probes from the Illumina TruSight Cardio Sequencing Kit. The hybridized
fragments were captured with magnetic beads, PCR-amplified, and sequenced using Illumina HiSeq
2500 and NextSeq technology. Reads were aligned to the Human Reference Genome (NCBI Genome
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Build 37) using the Burrow Wheelers Aligner algorithm [15], and post-processed in accordance with
Genome Analysis Toolkit version 3.4 (GATK) guidelines [16].
2.3. Selection of Candidate Genes
We focused on genes encoding cytoskeletal proteins in cardiomyocytes, which were reported
to be linked with DCM in previous literature [17]. Our candidate genes consisted of the following
genes: DMD (dystrophin), CRYAB (crystallin alpha B), DES (desmin), PDLIM3 (actin-associated LIM
protein), FKTN (fukutin), FKRP (fukutin-related protein), LAMA4 (laminin subunit alpha 4), and SGCD
(delta-sarcoglycan).
2.4. Evaluation of Identified Variants
Annotation of variant coding DNA and consequence of variants were performed using the tool
TransVar [18]. LOF variants were defined as variants leading to a premature stop codon in coding
DNA, or variants affecting splice donor or splice acceptor sites. In genes producing multiple protein
isoforms, we focused on isoforms expressed in atrial tissue. Isoform expression analysis was conducted
using the online database The Genotype Tissue Expression Database version 8 (GTEx v8) [19].
2.5. Pathway Analysis
We performed a pathway analysis of protein-protein interactions, using tool STRING [20].
Pathway analysis was performed on the human protein products of all genes in which LOF variants were
identified. The results were filtered, and interactions were assigned confidence scores. The methods for
calculating these confidence scores were described in detail elsewhere [21]. For each gene, we focused
on the ten protein-protein interactions with the highest confidence scores, and we excluded interactions
with a confidence score <0.700.
2.6. Statistical Analyses
Due to the small sample size, we used Fisher’s exact test for comparisons of variants in patients
versus controls. Using an LD regression score [19], we also examined the genetic correlation
between AF and 13 other traits: alcohol dependence, angina, body mass index (BMI), coronary heart
disease, depression, diabetes type 2, smoking, hand grip strength, heart failure, height, hypertension,
non-ischemic cardiomyopathy, and overall health rating. These analyses were based on a similar analysis
conducted in a previous study [22], modified to also include non-ischemic cardiomyopathy. The GWAS
data were derived from publicly available summary statistics, summarized in Table S1 (Supplementary
Materials). We applied Bonferroni correction to account for multiple testing, and p < 0.05/13 was
considered significant. Statistical analyses were performed using the software R, version 3.6.0.
J. Clin. Med. 2020, 9, 372 4 of 12
Table 1. Clinical characteristics of populations.
Early-Onset AF Cohort (n = 527) Control Cohort (n = 383)
Sex, male, n (%) 441 (83.6) 257 (67)
Age, years, median (IQR) 30 (24–36) a 71 (66–76) b
Height, cm, mean (SD) 183 (±9) 172 (±9)
Weight, kg, mean (SD) 89 (±17) 77 (±15)
BMI, kg/m2, mean (SD) 26 (±5) 26 (±5)
Comorbidities:
Hypertension, n (%) 0 (0) 246 (64.2)
Diabetes, n (%) 0 (0) 39 (10.2)
Heart failure, n (%) 0 (0) 0 (0)
Ischemic heart disease, n (%) 0 (0) 0 (0)
Valvular heart disease, n (%) 0 (0) 0 (0)
AF, atrial fibrillation; BMI, body mass index; IQR, interquartile range; SD, standard deviation. a Age of AF onset; b age at enrolment in cohort.
3. Results
3.1. Clinical Characteristics
We identified six patients with LOF variants in genes encoding cytoskeletal proteins. The clinical characteristics of the individuals with LOF variants are
summarized in Table 2. Four Danish patients (I through IV) harbored LOF variants in DMD, whereas two Norwegian patients carried LOF variants in FKTN
(patient V) and PDLIM3 (patient VI), respectively.
All six patients had very early onset of disease; the maximum age at onset of disease was 40 years. All four patients with DMD variants had onset of AF
before age 30 and were all diagnosed with persistent AF. Interestingly, five of the six patients were male, including all of the four patients with DMD variants,
making them hemizygous for the variants. The individuals with LOF variants in FKTN and PDLIM3 were both heterozygous for the variants.
Three of the six patients self-reported family history of AF (Table 2). These family members were unfortunately not available for genetic sequencing.
Table 2. Clinical characteristics of variant carriers.
Patient Gene Variant RefSNP Gender Genotype Onset of AF(age in years) AF Type
LVEF
(%)
Family History of AF
(self-reported)
I DMD p.D615Efs*6 rs752332058 Male Hemizygote 28 Persistent >55 No
II DMD p.D615Efs*6 rs752332058 Male Hemizygote 25 Persistent >55 Yes
III DMD c.10262+1G > A rs145603325 Male Hemizygote 21 Persistent >55 Yes
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Table 2. Cont.
Patient Gene Variant RefSNP Gender Genotype Onset of AF(age in years) AF Type
LVEF
(%)
Family History of AF
(self-reported)
IV DMD c.10262+1G > A rs145603325 Male Hemizygote 28 Persistent >55 No
V FKTN Chr9:108358933C > T NA Male Heterozygote 31 Paroxysmal NA No
VI PDLIM3 Chr4:186425651_186425652del NA Female Heterozygote 40 Paroxysmal >55 Yes
AF, atrial fibrillation; LVEF, left-ventricular ejection fraction; NA, not available; RefSNP, reference single-nucleotide polymorphism.
3.2. Genetic Variation
We identified four different LOF variants in three cytoskeletal genes. Two of the LOF variants were identified in DMD, one in FKTN, and one in PDLIM3.
Two Danish AF patients carried a variant in DMD, which affected the splice donor sites in multiple DMD isoforms expressed in cardiac tissue, notably
isoform Dp427m (ENST00000357033) and isoform Dp71b (ENST00000378723). In Dp427m, it affected the donor splice site between exon 71 and exon 72,
while affecting the donor splice site between exon 10 and 11 in Dp71b. Another variant in DMD was present in two other Danish patients. This variant
resulted in a frameshift in several DMD isoforms, including the isoforms Dp71b (ENST00000378723) and Dp260 (ENST00000358062). We identified the variant
FKTN p.Q54X that caused a stop codon in exon 3 in one Norwegian AF patient. Finally, one Norwegian individual harbored a frameshift variant in PDLIM3
(p.C246*fs*1), resulting in a premature stop-codon in exon 6. The characteristics of all variants are summarized in Table 3. Variants affecting multiple protein
isoforms are summarized in Table S2 (Supplementary Materials).
The association test showed a significantly larger proportion of LOF variants in cytoskeletal genes in early-onset AF patients compared with the controls
free of AF (p = 0.044).
Table 3. Loss-of-function variants identified in cytoskeletal genes.
Gene Genomic Position RefSNP Transcript Consequence Effect GnomAD MAF (%)
DMD ChrX:31140001_31140013del rs752332058 ENST00000378723 p.D615Efs*6 Frameshift variant 0.02491
DMD ChrX:31196048C>T rs145603325 ENST00000357033 c.10262+1G>A Splice donor 0.02689
FKTN Chr9:108358933C>T NA ENST00000223528 p.Q54* Nonsense variant NA
PDLIM3 Chr4:186425651_186425652del NA ENST00000284771 p.C246*fs*1 Frameshift variant NA
GnomAD, Genome Aggregation Database; MAF, minor allele frequency; NA, not available; RefSNP, reference single-nucleotide polymorphism.
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3.3. Genetic Correlation
We found a significant, moderate genetic correlation (rg = 0.40–0.59) between AF and non-ischemic
cardiomyopathy (rg = 0.42 (SE = 0.12); p = 3 × 10−4). We also found a significant, small correlation
between AF and heart failure (rg = 0.39 (SE = 0.05); p = 9 × 10−14), height (rg = 0.30 (SE = 0.02);
p = 5 × 10−33), hypertension (rg = 0.19 (SE = 0.02); p = 1× 10−12) BMI (rg = 0.17 (SE = 0.02); p = 4 × 10−12),
coronary heart disease (rg = 0.16 (SE = 0.02); p = 3 × 10−11), overall health rating (rg = 0.12 (SE = 0.03);
p = 1 × 10−5), smoking (rg = 0.08 (SE = 0.03); p = 1 × 10−3), and hand grip strength (left hand) (rg = 0.08
(SE = 0.03); p = 2 × 10−3). We found no significant genetic correlation between AF and alcohol
dependence, angina, depression, and diabetes type 2. Genetic correlation results are illustrated in
Figure 1.
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Correlations that were significant when accounting for multiple testing are marked in green. Bonf. adj.,
Bonferroni adjusted; BMI, body mass index; N.I. cardiomyopathy, non-ischemic cardiomyopathy.
3.4. Pathway Analysis
We found interactions between the protein products of DMD, FKTN, and PDLIM3 and numerous
other genes. DMD had protein-protein interactions with more than 10 other genes, with the TTN
gene among top ten interactions with highest confidence score. FKTN also interacted with more than
10 other genes, while PDLI 3 had protein-protein interactions with eight other genes. The top ten
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protein-protein interactions with highest confidence scores for all three genes are summarized in
Table S3 (Supplementary Materials). Interaction networks are illustrated in Figure 2.
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4. Discussion
In this study, we identified four different LOF variants in three cytoskeletal genes (DMD, FKTN,
and PDLIM3) carried by six individuals with early-onset AF. There was a significant enrichment of
LOF variants in cytoskeletal genes in the case population compared to an arrhythmia-free control
population, in which no individuals carried LOF variants.
4.1. Variants in DMD
Four Danish patients with early-onset AF carried two different LOF-variants in DMD.
The variant-carriers had a considerable burden of disease; all four presented with very early onset
of disease (age <30 years) and developed persistent AF (Table 3). Deleterious variants in DMD
are associated with the serious muscular dystrophies Duchenne and Becker, in which skeletal
muscle function is severely impaired along with serious cardiomyopathies [23]. However, none
of the participants harboring variants in DMD were diagnosed with skeletal muscle dysfunction.
DMD produces numerous isoforms [24], and predicting the effect of variants in the different isoforms
on cardiac function is challenging. Several cases of DMD-associated, X-linked cardiomyopathy without
a skeletal muscle phenotype were reported [25], which emphasizes the complex pathophysiology of
DMD variants. Notably, all four individuals with DMD variants were male and, therefore, hemizygous
for the variants. It is possible that these variants, while having arrhythmogenic effects in males, are less
pathogenic in females who have a second copy of the DMD gene.
Of the two DMD LOF variants, the frameshift variant (p.D615Efs*6) did not affect the primary
isoform expressed in skeletal and cardiac muscle, Dp427m. The variant did, however, affect several other
isoforms expressed in cardiac tissue, including Dp71b (ENST00000378723), a product of alternative
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splicing of the ubiquitously expressed Dp71(24), and numerous other isoforms such as Dp260
(see Table S2, Supplementary Materials). Although the exact function of these isoforms in the heart is
not yet known, the Dp71b isoform with the transcript ENST00000378723 is highly expressed in the
atria (Figure S1, Supplementary Materials), and previous studies showed the Dp260 isoform to be
expressed in cardiac tissue [26].
The DMD splice donor variant (c.10262+1G > A) affected numerous isoforms, including Dp427m,
an isoform important for the function of skeletal and cardiac muscle function. Interestingly, this variant
was previously reported in a patient who suffered from sudden cardiac death [27], which supports
possible proarrhythmic effects of the variant. Studies of lethal cardiac diseases in recent years
emphasizes that the pathogenicity of genetic variants in conserved genes may not be as malignant
as previously thought [28,29]. It is acknowledged that rare variants have different disease-causing
effects and that disease burden and severity are affected by a combination of rare and common
variants, in addition to other non-genetic factors [30]. Therefore, the DMD splice donor variant may
predispose to lethal arrhythmia in one individual while causing less lethal disease in another. The
variant c.10262+1G > A had a minor allele frequency (MAF) of 0.027% in gnomAD, indicating that it is
not a major contributor of highly malignant disease.
Additionally, pathway analysis (see Figure 2A) suggests protein-protein interactions between
DMD and several other genes expressed in the heart. Notably, DMD interacts with TTN, a gene which
was previously linked with AF [6,8].
4.2. Variants in FKTN and PDLIM3
We identified LOF variants in the cytoskeletal genes FKTN and PDLIM3 in two Norwegian
patients with early-onset AF. Both variants identified were novel and, to the best of our knowledge,
not reported elsewhere.
FKTN is associated with the rare muscular dystrophy, Fukuyama-type muscular dystrophy [31].
However, FKTN variants were in some cases also linked with DCM with minimal skeletal muscle
involvement [17,32], and our pathway analysis (Figure 2B) predicts protein-protein interactions
between the product of FKTN and the product of FKRP (fukutin-related protein), among others. FKRP
was previously associated with DCM [33].
Similarly, PDLIM3 was also associated with both DCM [17,34] and muscular dystrophy, in the
form of myotonic dystrophy [35]. The protein product of PDLIM3 is predicted to interact with the
protein products of several other genes that are linked with heart disease, including MYBPC3, ACTN2,
and CAV3 [13] (Figure 2C).
4.3. Atrial Cardiomyopathy
Our understanding of the pathophysiological disease mechanisms of disease-causing genetic
variants changed in recent years. Evidence from large-scale GWAS and high-throughput sequencing
projects [6,10] suggests that diseases, which previously were thought to have completely different
underlying mechanisms, may be more closely related, and even part of a continuum. For instance,
recent reports of an enrichment of titin-truncating variants (TTNtv) in familial and early-onset AF [8],
and the association of exonic SNPs in TTN with AF in a large GWAS [6] support the hypothesis of an
atrial cardiomyopathy [11].
Moreover, our analysis of genetic correlation between AF and other traits (Figure 1) shows a
significant genetic correlation between AF and non-ischemic cardiomyopathy (rg = 0.42; p = 3 × 10−4),
further supporting the hypothesis of atrial cardiomyopathy playing a role in AF development.
4.4. Treatment Consequences
Catheter ablation of AF is a class I recommendation when antiarrhythmic treatment fails [2].
Several studies showed that AF patients with a higher degree of fibrosis in the atria have higher
recurrence rates after catheter ablation [36]. It was, therefore, discussed whether ablative therapy is
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beneficial when AF occurs as a result of atrial cardiomyopathy [37]. Ongoing studies are evaluating
whether detection of fibrosis before ablation, using late gadolinium enhancement magnetic resonance,
may improve the ablation of AF in fibrotic hearts [38]. Several of the genes examined in this study
are linked with cardiac fibrosis. Cardiac fibrosis is a well-known clinical feature of DMD-associated
DCM [39], and PDLIM3 was shown to be involved in cardiac collagen deposition [40].
Finally, these patients might be at higher risk of tachycardia-induced cardiomyopathy in the
ventricles, as they are already predisposed for DCM by carrying variants in genes associated with
DCM. Understanding the pathogenesis of disease in patients carrying variants in these genes could
yield valuable knowledge about the treatment of AF and atrial cardiomyopathy.
4.5. Limitations
While the study included a relatively large number of participants, we only identified a total of
six patients with LOF variants. Four of these were in the DMD gene, likely because of its large size
(79 exons) and numerous isoforms, while only two of the variants were in other cytoskeletal genes.
Furthermore, most of the individuals with LOF variants were male, including the four carriers of DMD
variants, who were hemizygous for the variants. It cannot be excluded that these variants, or similar
LOF variants in cytoskeletal genes could have other effects in other population groups.
Several of the participants reported family members with AF. However, these individuals were
not genetically tested and, therefore, it was not possible to perform co-segregation analyses. The lack
of genetic testing of family members is a significant limitation of the study.
Furthermore, our genetic analyses were focused on genes encoding cytoskeletal proteins of
cardiomyocytes. These genes only represent a subgroup of structural genes associated with DCM,
and the results of this study cannot be extrapolated to all DCM-associated genes.
Therefore, while our data suggest a possible link between LOF variants in structural, cytoskeletal
genes and AF, our findings should be regarded as hypothesis-generating and be interpreted with caution.
5. Conclusions
We identified six individuals with LOF variants in three cytoskeletal genes in a cohort of 527
early-onset AF patients. We also found significant genetic correlation between AF and non-ischemic
cardiomyopathy using publicly available summary statistics from recent genome-wide association
studies. Our data suggest that cytoskeletal genes previously associated with ventricular cardiomyopathy
may also play a role in AF. Combined with numerous recent studies on other structural genes,
these data add to the hypothesis that structural genes could possibly predispose to development of
atrial cardiomyopathy.
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